Christina Curtis, PhD, MSc, a leader in cancer genomics at Stanford University, is applying her AI-driven research approaches that advanced breast cancer understanding to uncover osteosarcoma’s origins and new perspectives on therapy.
Advances in genetic sequencing and unprecedented collaboration among research institutions are helping scientists better predict prognosis, track treatment response, and move closer to personalized therapies for osteosarcoma.
With $15 million in funding, OSI and the broader osteosarcoma community, pediatric cancer foundations, and Break Through Cancer (BTC) have teamed up to bring BTC’s team-based approach to osteosarcoma, bringing together investigators from across the country and around the world.
Supported by the Osteosarcoma Institute and Ethos Discovery, the MIMIC trial evaluates a new method of removing lung metastases in dogs, providing insights that can directly inform human osteosarcoma treatment and drug development.